LONDON--(BUSINESS WIRE)--Technavio, a tech-focused research firm, has published a new report on
colorectal cancer drugs market, which is expected to grow at a
CAGR of nearly 4% from 2015-2019.
The new industry analysis report highlights the growing prevalence of
colorectal cancer, which is increasing worldwide. It is ranked as the
third most common type of cancer in North America, irrespective of
"According to the Canadian Cancer Society, colorectal cancer affected
more than 24,400 people in the country in 2014, and about 9,300
Canadians succumbed to the disease. The number of treatment-seeking
patients is expected to increase, which will lead to a rise in the
consumption of the drugs through the forecast period," says Faisal
Ghaus, Vice President of Technavio.
The new Technavio report also emphasizes the introduction of biologics
that are rapidly becoming the treatment of choice for colorectal cancer.
Biologics are targeted therapies, which act only on the malignant cells
and do not attack the healthy cells.
"The major biologics used for treating colorectal cancer include Erbitux
(cetuximab), Zaltrap (ziv-Aflibercept), Avastin (bevacizumab), and
Vectibix (panitumumab)," says Ghaus.
Technavio currently has
more than 3000 market research reports on a huge range of topics,
Technavio is a leading global technology research and advisory company.
Founded in 2003, Technavio has about 200 analysts globally and develops
over 2000 pieces of research every year, covering more than 500
technologies across 80 countries.
Technavio analysts employ primary as well as secondary research
techniques to ascertain the size and vendor landscape in a range of
markets. Analysts obtain information using a combination of bottom-up
and top-down approaches, besides using in-house market modeling tools
and proprietary databases. They corroborate this data with the data
obtained from various market participants and stakeholders across the
value chain, including vendors, service providers, distributors,
re-sellers, and end-users.
If you are interested in more information, please contact our media team
Know more here.